Literature DB >> 4772727

Anticholinergic withdrawal and benzhexol treatment in Parkinson's disease.

P M Horrocks, D J Vicary, J E Rees, J D Parkes, C D Marsden.   

Abstract

The effects of slow withdrawal of anticholinergic medication and addition of benzhexol (8 mg/day) have been studied in patients with Parkinson's disease on stable levodopa therapy. Withdrawal of anticholinergic drugs led to measurable and often severe deterioration in about two-thirds of patients. Addition of benzhexol produced a slight but definite additional improvement in those patients in whom anticholinergics were withdrawn before the trial. Anticholinergic drugs thus still have a part to play in the treatment of Parkinson's disease, for they produce benefit in addition to that provided by levodopa.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4772727      PMCID: PMC1083593          DOI: 10.1136/jnnp.36.6.936

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  3 in total

1.  Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action.

Authors:  J T Coyle; S H Snyder
Journal:  Science       Date:  1969-11-14       Impact factor: 47.728

2.  Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase.

Authors:  C D Marsden; P E Barry; J D Parkes; K J Zilkha
Journal:  J Neurol Neurosurg Psychiatry       Date:  1973-02       Impact factor: 10.154

3.  Levodopa in Parkinsonism: the effects of withdrawal of anticholinergic drugs.

Authors:  R C Hughes; J G Polgar; D Weightman; J N Walton
Journal:  Br Med J       Date:  1971-05-29
  3 in total
  6 in total

1.  L-dopa and carbidopa (sinemet) in the management of parkinsonism.

Authors:  E Critchley
Journal:  Postgrad Med J       Date:  1975-09       Impact factor: 2.401

Review 2.  Current drug therapy for Parkinson's disease. A review.

Authors:  R J Coleman
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

Review 3.  Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.

Authors:  B K Young; R Camicioli; L Ganzini
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

Review 4.  A risk-benefit assessment of drugs used in the management of Parkinson's disease.

Authors:  I Y Bodagh; D R Robertson
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

Review 5.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

Review 6.  Anticholinergics for symptomatic management of Parkinson's disease.

Authors:  R Katzenschlager; C Sampaio; J Costa; A Lees
Journal:  Cochrane Database Syst Rev       Date:  2003
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.